Most Read

The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across a wide range of therapeutic areas. Under the terms of

In line with the partnership with Janssen Pharmaceutica NV, Mundipharma now exclusively distributes and markets these treatments across 18 countries in the European Economic Area (EEA) and Switzerland.

Consequently, Teva is licensed to launch a generic version of Victoza as of 22 December 2023. Under certain circumstances Teva could launch a generic version of Victoza earlier,

Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates,

Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and

Hemlibra can be used in all age groups, and can also now be used at multiple dosing options (once weekly, every two weeks, or every four weeks) for

Dupixent can be used with or without topical corticosteroids. “For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control

The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with